BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.72), $0.45 worse than the analyst estimate of ($1.27). Revenue for the quarter came in at $341 thousand versus the consensus estimate of $625.81 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.